Navigation Links
Insulet Reports First Quarter 2008 Results
Date:5/13/2008

earch meeting in

April exploring different routes of administration of its BiTE antibody

MT110 for the treatment of cancer.

* Insulet is an industry partner in a majority of the sites supporting

the Juvenile Diabetes Research Foundation's Artificial Pancreas

Project. As a result of the OmniPod System's role in the project, John

Garibotto, Insulet's Vice President of Research, Development &

Engineering, has been invited to participate in an upcoming

FDA-NIH-JDRF workshop on engineering considerations for building

a closed loop system.

* In the first quarter, Insulet announced two development agreements as

part of the Company's strategy to leverage the OmniPod System for

ongoing innovation. The agreement with DexCom to integrate its

continuous glucose monitoring technology into the wireless, handheld

OmniPod System Personal Diabetes Manager (PDM). The amended agreement

with Abbott Diabetes Care, Inc establishes Abbott's Freestyle blood

glucose monitor will be the exclusive strip meter available in

OmniPod's PDM.

Financial Outlook for 2008

For the full year 2008, Insulet maintains its previously communicated guidance for full year 2008 revenue to be in the range of $40-45 million. The Company also maintains its expected 2008 net operating loss to be in the range of $55-60 million.

Conference Call

Insulet will host a conference call on Tuesday, May 13, 2008 at 5PM Eastern time to discuss the Company's first quarter 2008 results and present information concerning its business, strategies and outlook. To listen to the conference call, please dial 866-277-1182 for domestic callers and 617-597-5359 for international callers. The passcode is 40048264. A replay of the conference call will be available two hours after the start of the call through June 12, 2008 by dialing 888-286-8010 (domestic) an
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... ONOM@TOPIC and SilOnIS shared the ... most innovative and sustainable project in the ... smartcard platform for,citizenship and mobile multimedia applications ... for users,while adding value for network operators. ...
... Investor Update Conference Call Set for March 7, ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,it has entered into ... the privately-held specialty pharmaceuticals marketer which,Senetek licensed in ...
... 4 Osteotech, Inc.,(Nasdaq: OSTE ), a ... for,regenerative medicine, announced today that the Food and ... its Plexur,M(TM) Biocomposite. Adapting the Company,s proprietary Plexur(R),Technology, ... bony voids or gaps,of the skeletal system that ...
Cached Biology Technology:MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Senetek PLC in Dispute With Marketer of Pyratine-6(TM) 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 3
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... University of Nottingham have taken some important first steps ... a leading science journal reports. Dr Cameron Alexander ... of Pharmacy have used polymers long-chain molecules ... surfaces of a real cell. In work published ...
... by clean, local-source energy. Faster, more reliable technologies ... language. Medical care tailored to your DNA, or ... diseases and injuries. Five University of Pittsburgh ... health, and technology as part of Faculty Early ...
... Researchers from Weill Cornell Medical College may have discovered ... the world,s most common blood disorders, beta-thalassemia, commonly known ... is the most commonly inherited disease in the world, ... of every 100,000 African-Americans. The World Health Organization estimates ...
Cached Biology News:Life, but not as we know it? 2Pitt faculty receive awards to explore next-generation technologies 2Pitt faculty receive awards to explore next-generation technologies 3Pitt faculty receive awards to explore next-generation technologies 4Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 2Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 3Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 4
... DNA polymerase obtained by high level expression ... E. coli, Concentration: 5U/ul, Applications: Standard PCR ... the world leader in serving science. Thermo ... world healthier, cleaner and safer by providing ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: